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Abstract
 
Induction of transplantation tolerance with certain therapeutic nondepleting monoclonal anti-
bodies can lead to a robust state of peripheral “dominant” tolerance. Regulatory CD4
 
 
 
 T
cells, which mediate this form of “dominant” tolerance, can be isolated from spleens of toler-
ant animals. To determine whether there were any extra-lymphoid sites that might harbor
regulatory T cells we sought their presence in tolerated skin allografts and in normal skin.
When tolerated skin grafts are retransplanted onto T cell–depleted hosts, graft-infiltrating T
cells exit the graft and recolonize the new host. These colonizing T cells can be shown to con-
tain members with regulatory function, as they can prevent nontolerant lymphocytes from re-
jecting fresh skin allografts, without hindrance of rejection of third party skin. Our results suggest
that T cell suppression of graft rejection is an active process that operates beyond secondary
lymphoid tissue, and involves the persistent presence of regulatory T cells at the site of the
tolerated transplant.
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Introduction
 
In recent years significant advances have been made in en-
abling the therapeutic induction of transplantation toler-
ance (1–6). In rodents it is possible to induce a robust form
of peripheral tolerance by treatment with nondepleting
mAbs, such as the combination of anti-CD4 and anti-CD8,
at the time of transplantation (7–12). Tolerance so achieved
is dependent on regulatory T cells that disarm nontolerant
naive cells (dominant tolerance) and facilitate the emer-
gence of novel regulatory cells from the naive lymphocyte
population (infectious tolerance; references 8, 10, and 13).
The regulatory cells which fulfill this role are known to be
CD4
 
 
 
 (8), and contained in both the CD4
 
 
 
CD25
 
 
 
 and
CD4
 
 
 
CD25
 
 
 
 populations (14).
It has been repeatedly demonstrated that such regulatory
T cells can be isolated from spleens of tolerant mice (8, 12,
15). Recent work has suggested that in tolerant rats T cells
infiltrating tolerated kidneys are enriched for regulatory
cells when compared with the splenic T cells (16). We
show here that tolerated skin grafts possess regulatory T
cells with the capacity to mediate dominant transplantation
tolerance. The presence of regulatory T cells in tolerated
grafts may indicate that they have a protective role within
that tissue.
 
Materials and Methods
 
Mice.
 
CBA/Ca (H-2
 
k
 
), human-CD52 transgenic CP1-
CBA/Ca (H-2
 
k
 
; reference 17), recombination activating gene
(RAG)1
 
 
 
/
 
 
 
-CBA/Ca (H-2
 
k
 
), and B10.BR (H-2
 
k
 
) mice were
bred and maintained in the SPF facilities of the Sir William Dunn
School of Pathology (Oxford, UK). All groups were age and sex
matched. All procedures were conducted in accordance with the
Home Office Animals (Scientific Procedures) Act of 1986.
 
Thymectomy and Skin Grafting.
 
Mice were anesthetized with a
mixture of 10 mg/ml Hypnodil and 2 
 
 
 
g/ml Sublimaze (Janssen).
0.12 ml per 20 g of body weight was injected intraperitoneally.
Thymectomy was conducted as described by Monaco et al. (18).
In short, a longitudinal incision was made on the anterior surface
of the neck, and the thymus was removed as two intact lobes by
the application of negative pressure through a glass tip inserted in
the anterior mediastinum. Skin grafting was conducted according
to a modified technique of Billingham et al. (19). Briefly, full
thickness tailskin (1 
 
 
 
 1 cm) was grafted on the lateral flank.
Grafts were observed on alternate days after the removal of the
bandage at day 8 and considered rejected when no viable donor
skin was present. Tolerated skin grafts were removed from the
flank of tolerant mice, washed in PBS and grafted on the lateral
flank of the new hosts. Statistical analysis of graft survival was
made by the log rank method (20).
 
Adoptive Cell Transfer.
 
Cells were obtained from spleens of
adult CBA/Ca mice. A single cell suspension was obtained by
passing the splenocytes through a 70-
 
 
 
m cell strainer (Becton
Dickinson) and the erythrocytes were depleted by water lysis.
Cells were counted, diluted in PBS, and injected intravenously
into the tail vein.
 
Cell Depletion, Tolerance Induction, and mAbs.
 
For depletion of
CP1-CBA T cells, 0.25 mg of CAMPATH-1H (21) was injected
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intraperitoneally. Tolerance was induced in CBA/Ca and CP1-
CBA mice by treatment with 1 mg nondepleting CD4 mAb
(YTS177.9; reference 7) and 1 mg nondepleting CD8 mAb
(YTS105.18; reference 7) at day 0, 2, and 4 after B10.BR skin
transplantation. These mAbs were produced in our laboratory by
culture in hollow fiber bioreactors, purified from culture super-
natants by 50% ammonium sulfate precipitation, dialyzed against
PBS, and the purity checked by native and SDS gel electrophore-
sis (PhastGel; Amersham Pharmacia Biotech).
 
Flow Cytometric Analysis.
 
Peripheral blood samples were de-
pleted of erythrocytes by water lysis, washed and resuspended in
PBS, 1% wt/vol BSA, 5% vol/vol heat-inactivated normal rab-
bit serum, and 0.1% wt/vol sodium azide. Cells were incubated
for 45 min at 4
 
 
 
C with directly conjugated CD3(KT3)-FITC,
CD25(PC61)-PE (BD PharMingen), and CD4(H129.19)-Cy-
Chrome (BD PharMingen). The cells were washed, resus-
pended in PBS, 1% wt/vol BSA, 0.1% wt/vol sodium azide, and
fixed in 2% vol/vol formaldehyde solution. Three-color FACS-
Calibur™ analysis was performed using CELLQuest™ software
(Becton Dickinson).
 
Results and Discussion
 
Tolerated Skin Grafts Can Transfer Dominant Tolerance
When Regrafted Onto New Recipients.
 
We investigated
whether tolerated skin from animals exhibiting dominant
tolerance play host to regulatory T cells. First, we estab-
lished that the regrafting of tolerated B10.BR skin trans-
plants into T cell–depleted hosts leads to a dominant toler-
ant state, such that adoptively transferred splenocytes from
naive donors are prevented from rejecting fresh allografts
(Fig. 1).
Tolerated B10.BR skin grafts, as well as control CBA/
Ca skin, were obtained from CBA/Ca mice 100 to 120 d
after skin grafting, such tolerance having been induced ini-
tially with 3 doses of 1 mg nondepleting CD4 and CD8
mAbs given over 1 wk. T cell–depleted CP1-CBA mice
were used as recipients for the regrafted skin. The CP1-
CBA strain is histocompatible with CBA/Ca and expresses
human-CD52 under the control of the CD2 promoter in
all T cells, allowing selective T cell depletion with the
hCD52 mAb CAMPATH-1H (13). “Recipient” CP1-
CBA mice were thymectomized at 4 wk of age, and de-
pleted of T cells with CAMPATH-1H 1 wk before skin
grafting (designated as “empty” mice). 30 d after the graft-
ing of these empty CP1-CBA mice with tolerated B10.BR
or control CBA/Ca skin grafts, all mice were transfused
with 10
 
7
 
 splenocytes from naive CBA/Ca donors and chal-
lenged with a fresh B10.BR skin graft. Fig. 2 A shows that
the group of mice, that had been transplanted with toler-
ated B10.BR skin grafts, were able to resist the rejection by
naive cells. However, groups transplanted with CBA/Ca
skin from the same tolerant donors were permissive for re-
jection, with a rate similar to the animals grafted with
CBA/Ca skin from naive donors, and to the control recip-
ients that had not received any preparatory skin graft.
To confirm that tolerant animals were not immunosup-
pressed, we showed that the same recipient test animals re-
mained permissive for rejection of third-party skin. BALB/c
and fresh B10.BR skin were transplanted in the same graft
bed of mice of the nonpermissive group. Fig. 2 B shows
that the third-party BALB/c skin grafts were promptly re-
jected while the B10.BR skin grafts were accepted indefi-
nitely.
Taken together, these results confirm that only the toler-
ated skin grafts, but not autologous skin from tolerant ani-
mals, have the capacity to transfer dominant tolerance.
 
Tolerance Is Not Due to Microchimerism.
 
There is evi-
dence implicating donor microchimerism as a mechanism
capable of enhancing graft acceptance (22, 23). To investi-
gate whether microchimerism was the explanation for tol-
erance induced by transfer of tolerated skin grafts, we re-
peated the experiment but this time grafting CBA/Ca mice
with skin from (B10.BR 
 
 
 
 CBA/Ca)F
 
1
 
. Such skin grafts
could contribute to the generation of donor-type micro-
chimerism with cells simultaneously carrying CBA/Ca and
B10.BR antigens and being naturally tolerant, by deletion,
to both sets of antigens (without B10.BR-specific regula-
tory T cells). “Empty” CP1-CBA mice were transplanted
with tolerated B10.BR skin grafts from tolerant CBA/Ca,
another group with (B10.BR 
 
 
 
 CBA/Ca)F
 
1
 
 skin grafts
transplanted previously in syngeneic F
 
1
 
 mice, and yet an-
other group with fresh (B10.BR 
 
 
 
 CBA/Ca)F
 
1
 
 skin. In
one control group, the empty CP1-CBA received no
grafts. A challenge intravenous injection with 10
 
7
 
 spleen
cells from naive CBA/Ca was administered to all CP1-
CBA mice 30 d after grafting. All mice received a new
B10.BR skin graft on the following day. Fig. 3 shows that
only the animals grafted with tolerated B10.BR skin from
Figure 1. The experimental system. CBA/Ca or CP1-CBA were made
tolerant to B10.BR skin grafts by treatment with nondepleting CD4 and
CD8 mAbs. 100 d after tolerance induction the tolerated skin grafts, or
autologous control skin, were removed and transplanted onto “empty”
mice (either adult thymectomized and T cell–depleted CBA-CP1 mice,
or RAG1 / -CBA mice). After 30 d the mice were transfused with 107
splenocytes from naive CBA/Ca mice, together with a fresh B10.BR skin
graft. The possible outcomes are: rejection, when a nontolerant preexist-
ing state permits the transfused cells to mediate graft rejection; or accep-
tance of the skin grafts, when tolerated grafts lead to a tolerance state that
is nonpermissive for graft rejection by the transfused splenocytes. 
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tolerant CBA/Ca were nonpermissive for naive cells to re-
ject the B10.BR skin grafts. The empty mice, which had
been grafted with (B10.BR 
 
 
 
 CBA/Ca)F
 
1
 
 skin, remained
permissive and skin was rejected at rate similar to controls.
These results exclude microchimerism as being sufficient
to drive tolerance achieved by transferring tolerated skin
grafts. In addition, we can exclude any requirement for the
thymus in the maintenance of the tolerant state, as all recip-
ient mice had been adult thymectomized.
 
Tolerance Is Due to Regulatory T Cells Present in the Skin
Graft.
 
To establish the role of putative regulatory T cells
infiltrating the skin graft we used CP1-CBA mice, toler-
ized to B10.BR skin grafts, as donors of tolerated B10.BR
skin. This enabled us to use CAMPATH-1H mAb to de-
plete donor T cells present in the tolerated skin, once it had
been retransplanted. Fig. 4 shows that when tolerated skin
was obtained from tolerant CBA/Ca donors, hosts became
nonpermissive for the rejection of fresh B10.BR skin graft
after transfusion of 10
 
7
 
 nontolerant spleen cells. However,
when the tolerated B10.BR skin was derived from tolerant
CP1-CBA donors, and the hosts depleted of all donor-
derived and recipient T cells with 0.25 mg CAMPATH-
1H at the time of regraft, grafts were rejected after the
transfusion of naive CBA/Ca splenocytes.
From these results we can conclude that when any T
cells carried over with tolerated skin grafts are depleted,
then tolerance is not imposed on the recipient. As a corol-
lary, when we observe nonpermissiveness, it must be due
to regulatory T cells which had infiltrated the tolerated
skin grafts, and not to other pro-tolerogenic properties of
the tolerated skin, as in the example of neonatal tolerance
(24, 25).
 
T Cells Can Expand from the Tolerated B10.BR Skin
Grafts.
 
We used RAG1
 
 
 
/
 
 
 
-CBA mice as T cell–deficient
hosts to determine whether T cells infiltrating tolerated
grafts can expand from the skin. These mice were grafted
with tolerated B10.BR skin from either tolerant CBA/Ca
or tolerant CP1-CBA, or autologous CBA/Ca skin from
CBA/Ca mice tolerant to B10.BR skin grafts. A sample of
peripheral blood was collected 30 d after transplantation,
stained, and analyzed by flow cytometry. Fig. 5 A shows
that CD4
 
 
 
 T cells can be detected in the peripheral blood
of transplanted RAG1
 
 
 
/
 
 
 
-CBA mice 30 d after tolerated
skin transplantation. Remarkably, the CD4
 
 
 
 T cell fre-
quency was significantly increased in recipients of tolerated
skin grafts when compared with recipients of autologous
skin from tolerant mice. In all mice the majority of CD4
 
 
 
cells that had expanded from the graft were CD4
 
 
 
CD25
 
 
 
,
but a minority of CD4
 
 
 
CD25
 
 
 
 cells could also be detected
(Fig. 5 B). The frequency of CD4
 
 
 
CD25
 
 
 
 T cells within
the CD4
 
 
 
 T cell population derived from tolerated skins
was not significantly different from the usual frequency in
naive CBA/Ca mice. 1 wk after the blood sampling, all an-
imals were transfused with 10
 
7
 
 spleen cells from naive
Figure 2. Tolerated skin grafts can transfer the tolerant state upon re-
graft. CP1-CBA mice were thymectomized at 4 wk of age, and depleted
of T cells with 0.25 mg CAMPATH-1H. (A) At day  30, these mice
were transplanted with tolerated B10.BR skin grafts from tolerant
CBA/Ca ( ), CBA/Ca skin from the CBA/Ca tolerant to B10.BR skin
grafts ( ), or CBA/Ca skin from naive donors ( ). A control group of
mice did not receive any initial skin graft ( ). All mice were transfused
with 107 spleen cells from naive CBA/Ca at day  1, and transplanted
with a fresh B10.BR skin on the following day. Only mice with tolerated
skin grafts resisted the challenge transfusion of nontolerant splenocytes
and accepted the B10.BR skin grafts indefinitely ( , n   5, MST  
100 d, P   0.002 to other groups). In all other groups the B10.BR skin
grafts were rejected at a similar rate. (B) Tolerant mice were grafted with
both BALB/c ( ) and B10.BR ( ) skin grafts in the same graft bed, 60 d
after challenge with naive CBA/Ca splenocytes and a fresh B10.BR skin.
Only BALB/c skin grafts were rejected (P   0.007).
Figure 3. Tolerance is not due to microchimerism. Empty CP1-CBA
mice were transplanted at day  30 with tolerated B10.BR skin grafts
from tolerant CBA/Ca ( ), (B10.BR   CBA/Ca)F1 skin grafts ( ), or
(B10.BR   CBA/Ca)F1 skin grafts transplanted 30 d before into synge-
neic hosts ( ). A control group of mice did not receive any initial skin
graft ( ). All mice were transfused with 107 spleen cells from naive
CBA/Ca at day  1, and transplanted with a fresh B10.BR skin on the
following day. Only recipients of tolerated skin grafts resisted the transfu-
sion of nontolerant splenocytes and accepted the B10.BR skin grafts in-
definitely ( , n   5, MST   100 d, P   0.002). In all other groups the
B10.BR skin grafts were rejected at a similar rate. 
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CBA/Ca mice, and challenged with a fresh B10.BR skin
graft on the following day. In one group of mice trans-
planted with tolerated B10.BR skin from tolerant CP1-
CBA donors, donor T cells were depleted with 0.25 mg
CAMPATH-1H at the time of CBA/Ca cell transfusion.
These mice became permissive for rejection by naive
CBA/Ca cells, with a rejection rate comparable to the
group initially grafted with CBA/Ca skin from tolerant
CBA/Ca mice (Fig. 5 C). In contrast, when the RAG1
 
 
 
/
 
 
 
-CBA mice were initially transplanted with tolerated
B10.BR skin grafts, in the absence of T cell depletion, all
mice became nonpermissive for rejection, and conse-
quently all B10.BR grafts were held indefinitely.
We needed to exclude the possibility that the process of
transplanting donor skin to RAG1
 
 
 
/
 
 
 
-CBA recipients was
not itself conducive to the development of dominant toler-
ance. We first transplanted CBA/Ca mice with B10.BR
skin grafts in the absence of any further treatment. At day 8
after transplantation, when the skin grafts still appeared
healthy (rejection usually occurs at days 11–15), the grafts
were removed and retransplanted onto RAG1
 
 
 
/
 
 
 
-CBA
mice. These grafts were all rejected (
 
n
 
 
 
  
 
6, median survival
time [MST] 
 
  
 
9 d from the time of regraft) and contrib-
uted to CD4
 
 
 
 T cell expansion as assessed 30 d after trans-
plantation (4.92% 
 
 
 
 0.37 CD4
 
 
 
 T cells in peripheral
blood). After transfusion of 10
 
7
 
 splenocytes from naive
CBA/Ca and transplantation of a second skin graft we con-
firmed that the cell expansion did not alter the rejection
permissive state, as all skin grafts were readily rejected (
 
n
 
 
 
 
 
6, MST 
 
  
 
17 d). This reinforces our conclusion that the
regulatory T cells preexisted in tolerated skin before re-
transplantation onto RAG1
 
 
 
/
 
 
 
-CBA recipients.
We have recently shown that B10.BR skin graft rejec-
tion mediated by 10
 
7
 
 splenocytes transfused from naive
CBA/Ca into empty CP1-CBA mice, can be prevented by
cotransfer of regulatory T cells (14). By titrating the num-
ber of transfused regulatory cells we concluded that abroga-
tion of rejection requires cotransfer of 10
 
6
 
 CD4
 
 
 
CD25
 
 
 
cells or 10
 
7
 
 CD4
 
 
 
CD25
 
 
 
 cells from CBA/Ca tolerized to
B10.BR skin grafts (14). Such observations, taken together
with our present results, suggest that at the time 10
 
7
 
 spleno-
cytes from naive CBA/Ca mice are transfused, regulatory
Figure 4. Tolerance is due to regulatory T cells present in the skin
graft. Empty CP1-CBA mice were transplanted at day  30 with toler-
ated B10.BR skin grafts from tolerant CBA/Ca ( ), tolerated B10.BR
skin grafts from tolerant CP1-CBA ( ), or (B10.BR   CBA/Ca)F1 skin
( ). A control group of mice did not receive any initial skin graft ( ).
All mice were transfused with 107 spleen cells from naive CBA/Ca at day
 1, and transplanted with a fresh B10.BR skin on the following day.
Mice transplanted with tolerated B10.BR skin grafts from tolerant
CP1-CBA ( ) were depleted of infiltrating T cells by treatment with
0.25 mg CAMPATH-1H at days  30 and  1. Recipients of tolerated
B10.BR skin grafts from tolerant CBA/Ca were also treated with CAM-
PATH-1H as described. Only recipients of tolerated skin grafts whose T
cells had not been ablated resisted the transfusion of nontolerant spleno-
cytes and accepted B10.BR skin grafts indefinitely ( , n   5, MST  
100 d, P   0.002). In all other groups the B10.BR skin grafts were re-
jected at a similar rate. Note that one animal in the tolerated skin, T cell–
depleted group ( ) rejected the initial B10.BR graft before transfusion
with CBA/Ca splenocytes.
Figure 5. T cells expand from the tolerated B10.BR skin grafts.
RAG1 / -CBA mice were grafted with tolerated B10.BR skin from tol-
erant CBA/Ca mice ( ), CBA/Ca skin from CBA/Ca mice tolerant to
B10.BR skin grafts ( ), and tolerated B10.BR skin grafts from tolerant
CP1-CBA mice (  and  ). Tolerated B10.BR skin grafts in group  
were depleted of putative infiltrating T cells with 0.25 mg CAMPATH-
1H at day  1. (A) Blood samples were collected 30 d after skin grafting
and analyzed by FACS®. The graph represents the percentage of CD4  T
cells within blood mononuclear cells. The percentage of CD4  T cells
that expanded from tolerated skin grafts is significantly higher than in the
animals grafted with CBA/Ca skin from tolerant syngeneic donors (P  
0.05, unpaired t test). (B) FACS® staining from a mouse of the tolerated
skin group ( ), showing that expanded T cells are mainly CD4 CD25 .
(C) All mice were transfused with 107 spleen cells from naive CBA/Ca 1
wk after blood tests, and transplanted with a fresh B10.BR skin on the
following day (day 0). Recipients of tolerated B10.BR skin grafts whose
putative regulatory T cells had not been depleted resisted the challenge
with transfused CBA/Ca splenocytes and accepted the B10.BR skin grafts
indefinitely (  and  , MST   100 d, P   0.05). Mice that were recipi-
ents of tolerated B10.BR skin grafts depleted of T cells rejected the grafts
shortly after transfusion of CBA/Ca splenocytes ( , MST   22 d). Re-
cipients of CBA/Ca skin from CBA/Ca mice tolerated to B10.BR skin
grafts also rejected B10.BR skin grafts ( , MST   20.5 d).1645 Graca et al. Brief Definitive Report
cells from tolerated allografts have expanded to evoke regu-
latory function equivalent to 106 CD4 CD25  cells from a
tolerized spleen.
These results confirm that tolerance achieved by retrans-
plantation of tolerated skin grafts is due to regulatory T
cells that infiltrate the transplant, and are not present (at
least at comparable levels) within the autologous skin of
such tolerized mice. This observation may in part explain
the phenomenon of linked suppression, that could operate
at the level of the graft, therefore yielding graft acceptance
when the tolerated and “third-party” antigens coexist in
close proximity, usually on the same cells. In contrast to the
situation where the two sets of antigens are present in two
different grafts in the same graft-bed, when the third party
graft is rejected (9, 10, 26, 27).
Interestingly, a reverse transcription (RT)-PCR analysis
of genes expressed in tolerated and rejecting tissues,
showed that genes associated with regulatory T cells were
found to be differential. This was not, however, the case,
when draining lymph nodes or spleens from the same ani-
mals were compared, suggested that regulatory activity is
concentrated in the graft (28). It is intriguing that on a
functional basis, regulatory cells with the capacity to pre-
vent graft rejection can be demonstrated in both the spleen
and tolerated skin grafts. It is not clear at this time, given
the RT-PCR data, whether graft infiltrating regulatory
cells constitute a special resident population different from
splenic regulatory cells. The observation that T cells ex-
pand from graft infiltrating regulatory cells may imply that
regulatory T cells in grafts result from a steady-state recir-
culation. Perhaps, regulatory cells recirculate through the
body and accumulate preferentially at the sites where their
target antigens are present. As a consequence it is possible
they exert their regulatory activity on peripheral tissues by
default, until inflammatory signals or other as yet unknown
ligands turn off their suppressive function, so permitting a
“normal” protective immune response to occur. In any
case, our observations strongly support the view that at least
some of the suppressive activity of regulatory T cells occurs
beyond secondary lymphoid tissues at the sites where their
target antigens are present.
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